Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- I watched more than 500 new movies this year. These are the 25 best ones.
- NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- Bowen Yang is reportedly leaving 'Saturday Night Live' after this week's episode
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- What to know about cheese voluntarily recalled in 20 states
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Flash flooding causes highways to close to and from Eilat
